This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.

About this trial

Last updated 15 years ago

Study ID

PM025

Status

Completed

Type

Observational

Placebo

No

Accepting

18-75 Years
20 to 57 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 16 years ago

What is this trial about?

It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

What are the participation requirements?

Yes

Inclusion Criteria

- Participation & completion of the NC-100 Clinical Trial. - Able and willing to sign an Informed Consent.

No

Exclusion Criteria

none